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Osteoclasts are myeloid lineage-derived bone-resorbing cells of hematopoietic origin.
They differentiate from myeloid precursors through a complex regulation process where
the differentiation of preosteoclasts is followed by intercellular fusion to generate large
multinucleated cells. Under physiological conditions, osteoclastogenesis is primarily
directed by interactions between CSF-1R and macrophage colony-stimulating factor
(M-CSF, CSF-1), receptor activator of nuclear factor NF-κB (RANK) and RANK ligand
(RANKL), as well as adhesion receptors (e.g., integrins) and their ligands. Osteoclasts
play a central role in physiological and pathological bone resorption and are also required
for excessive bone loss during osteoporosis, inflammatory bone and joint diseases
(such as rheumatoid arthritis) and cancer cell-induced osteolysis. Due to the major
role of osteoclasts in these diseases the better understanding of their intracellular
signaling pathways can lead to the identification of potential novel therapeutic targets.
Non-receptor tyrosine kinases and lipid kinases play major roles in osteoclasts and
small-molecule kinase inhibitors are emerging new therapeutics in diseases with
pathological bone loss. During the last few years, we and others have shown that certain
lipid (such as phosphoinositide 3-kinases PI3Kβ and PI3Kδ) and tyrosine (Src−family
and Syk) kinases play a critical role in osteoclast differentiation and function in humans
and mice. Some of these signaling pathways shows similarity to immunoreceptor-like
receptor signaling and involves important other enzymes (e.g., PLCγ2) and adapter
proteins (such as the ITAM−bearing adapters DAP12 and the Fc-receptor γ-chain).
Here, we review recently identified osteoclast signaling pathways and their role in
osteoclast differentiation and function as well as pathological bone loss associated
with osteolytic tumors of the bone. A better understanding of osteoclast signaling may
facilitate the design of novel and more efficient therapies for pathological bone resorption
and osteolytic skeletal metastasis formation.
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DEVELOPMENT AND FUNCTION OF OSTEOCLASTS AND
THEIR ROLE IN PATHOLOGICAL BONE LOSS
Bone tissue plays a crucial role in structural support and movement of the body as well as it
stores minerals. It also hosts the bone marrow, which is the major site of postnatal hematopoiesis
(Zaidi, 2007). Bone matrix is an essential component of the bone and it is built up from inorganic
salts and organic matrix. Besides providing structural support, bone matrix also stores a wide
range of growth factors capable of regulating normal bone homeostasis. Bone microenvironment
contains a wide repertoire of cellular elements: hematopoietic and mesenchymal stem cells,
chondrocytes, fibroblasts, adipocytes, endothelial and nerve cells as well as the bone cells themselves
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(Arron and Choi, 2000). The most well-known of these
latter ones are bone-resorbing osteoclasts, bone-forming
osteoblasts and osteocytes regulating the bone remodeling
process (Bonewald, 2011).
Osteoclasts are derived from myeloid precursors, which
express several cytokine receptors. Osteoclast differentiation is
mainly governed by receptor activator of NF-κB ligand (RANKL)
and macrophage colony-stimulating factor (M-CSF or CSF-1),
as well as integrin and immunoreceptor-like adhesion signals
and interactions, which are provided by osteoclastogenesis-
supporting cells, such as osteoblasts, osteocytes and other stromal
cells under physiological conditions (Boyle et al., 2003). The
early phase of osteoclast differentiation is characterized by
the expression of osteoclast-specific genes, such as tartrate-
resistant acidic phosphatase (TRAP) in committed precursors
(preosteoclasts). Fusion of these preosteoclasts will then lead
to formation of large, multinucleated osteoclasts. These giant
polykarions spread over the bone surface and digest the
underlying bone tissue through the simultaneous release of
hydrochloric acid and digestive enzymes onto the bone
(Teitelbaum, 2000).
The tightly regulated balance between bone resorption and
bone formation can be altered under pathological conditions.
Enhanced maturation and activation of osteoclasts leads to
pathological bone resorption as seen in osteoporosis and
inflammatory bone diseases (Győri and Mócsai, 2015). During
the pathogenesis of inflammatory bone diseases such as
rheumatoid arthritis, gout and periodontitis, the chronic
inflammation irreversibly affects the surrounding bone tissue.
Bone degradation in inflammatory arthritis is best characterized
in human rheumatoid arthritis (Győri and Mócsai, 2015).
Rheumatoid arthritis is a chronic autoimmune disease, eventually
leading to the destruction of surface cartilage and subchondral
bone primarily in the small synovial joints of the hands and feet
(Firestein, 2003). Osteoclasts play a key role in the pathogenesis of
rheumatoid arthritis (McInnes and Schett, 2007) and numerous
studies focused on the crosstalk between osteoclast and the
immune system in rheumatoid arthritis. Mature osteoclasts are
present at the sites of bone destruction and osteoclastogenesis is
enhanced in the close proximity of the inflamed joints (Schett
and Teitelbaum, 2009). This pronounced osteoclast formation
is due to the accumulation of osteoclast precursors at the sites
of erosion and enhanced maturation of these preosteoclasts to
bone-resorbing polykarions in the presence of osteoclastogenic
cytokines derived from the immune and stromal cells (Schett,
2009). Besides inflammatory bone diseases and osteoporosis, the
third major disease where excessive bone loss occurs due to
hyperactivation of osteoclasts is tumor-induced osteolysis and the
formation of bone metastases.
ROLE OF OSTEOCLASTS IN
TUMOR-INDUCED OSTEOLYSIS AND
BONE METASTASIS FORMATION
Bone tissue is one of the most common sites for metastasis
formation by a large number of solid tumors including
lung, prostate, breast, thyroid, colorectal, ovarian cancers,
and malignant melanoma. Further, two-third of patients
with stage II/III prostate and breast cancers develop bone
metastasis (Hernandez et al., 2018). Bone metastases are
classified as osteolytic, osteoblastic and mixed lesions. The
role of osteoclasts and induction of osteoclastogenesis is
best described in the process of osteolytic bone metastasis
formation. The presence of osteolytic bone lesions are associated
with a set of different morbidities including pathological
fractures, pain and hypercalcemia (Weilbaecher et al., 2011),
seriously affecting the patient’s wellbeing and life expectancy
(Coleman and Rubens, 1987).
Although solid tumors capable of forming osteolytic lesions
have proteolytic activity, the extent of this is far from being able
to break down the bone matrix. Degradation of both the organic
and inorganic components of the bone is therefore carried out by
osteoclasts, the unique bone-resorbing cells, accumulating in the
vicinity of tumor cells forming osteolytic metastases (Croucher
et al., 2016). Tumor cells can promote osteoclast-mediated
osteolysis via several mechanisms. Either tumor cells can induce
osteoclast differentiation directly via the expression of RANKL or
they can stimulate osteoclastogenesis indirectly via the activation
of osteoblasts (Mundy, 2002). During this latter process, a wide
range of tumor cell-derived growth factors such as parathyroid
hormone related peptide – (PTHrP) can induce the expression of
RANKL on osteoblasts, which in turn drives the differentiation of
multinucleated osteoclasts from myeloid precursors (Suva et al.,
1987). Mature osteoclasts then resorb the bone matrix and allow
tumor cells to grow and spread within the tissue.
Skeletal metastases formation is a self-perpetuating cycle
where tumor cells and bone-resorbing osteoclasts are enrolled
in a “vicious” cycle characterized by the release of bone-stored
growth factors by osteoclast-mediated bone resorption, which
further stimulates cancer cell survival and proliferation (Faccio,
2011). Malignant cells express a wide range of growth factors and
cytokines, which can directly or indirectly activate osteoclasts.
On the other hand, osteoclast-mediated bone resorption can
lead to the release of bone-stored cytokines including TGFβ,
which are able to promote cancer cell survival and growth
(Kakonen et al., 2002). Bone matrix-derived cytokines can
also provide a chemotactic stimulus for directed cancer cell
migration (Orr et al., 1979). Further, RANKL itself via a
paracrine mechanism can serve as a chemoattractant and
increase migration of RANK-positive cancer cells (Jones et al.,
2006). As a consequence, osteoclast-mediated osteolysis results
in an altered bone microenvironment, which facilitates cancer
growth and metastasis formation. Later during the disease,
these interactions between tumor and bone cells result in
a locked cycle of tissue destruction and cancer growth
(“vicious cycle” of bone metastasis formation) (Roodman and
Dougall, 2008). In line with this, it has been found in
mice, that cancer cells, which are more closely located to
the bone surface showed increased proliferation compared
to the ones distant from the bone (Kostenuik et al., 1992).
Underlying the role of osteoclasts in the process of bone
metastasis formation, bisphosphonate pyrophosphate analogs
that target osteoclasts are used to prevent bone destruction
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and modify progression of skeletal metastasis in cancer
(Choi et al., 2009).
Bone remodeling is also closely coupled with the lympho-
hematopoietic system. The similarity between the signaling
mechanism of the bone and immune systems in this
shared microenvironment indicate that cancer cell growth
associated with osteolytic bone degradation can also drive local
immunosuppression and accumulation of metastasis-promoting
immune cell populations (Lorenzo et al., 2007). A large body of
experimental evidence has implicated the role of the immune
system in the regulation of bone homeostasis both in humans
and mice (Lorenzo et al., 2010).
INTERPLAY BETWEEN THE SKELETAL
AND IMMUNE SYSTEMS DURING BONE
METASTASIS FORMATION
Tumor development can alter both the skeletal and immune
homeostasis (Nakashima and Takayanagi, 2009). Malignant cells
are able to suppresses certain effector immune cells subsets,
such as conventional CD8+ T cells, which can recognize and
kill cancer cells (Schreiber et al., 2011). Other immune cells,
such as regulatory T cells (Tregs), myeloid-derived suppressor
cells (MDSC) and tumor-associated macrophages (TAMs) also
play important roles in promoting cancer growth and metastasis
formation. On the other hand, the cellular elements and humoral
factors of the innate and adaptive immune systems can affect
osteoclastogenesis as well (Takayanagi, 2010). Macrophages and
dendritic cells also share common precursors with osteoclasts,
which underline the importance of the field of osteoimmunology
(Takayanagi, 2007).
While Th1 and Th2 cytokines exert an inhibitory effect on
osteoclastogenesis, the IL-17 producing T helper type 17 (Th17)
cells have been described to be highly osteoclastogenic (Sato
et al., 2006b). Th17 cells can express high levels of RANKL and
as a consequence directly promote osteoclastogenesis. Moreover,
they may activate inflammation locally, leading to the release
of proinflammatory mediators (e.g., TNF-α, IL-1, and IL-6),
which can potentiate RANKL expression on osteoclastogenesis-
supporting cells (Sato et al., 2006b). Further, Th17 cells were
described to activate osteoclastogenesis-driven osteolysis through
RANKL production during inflammatory arthritis (Okamoto and
Takayanagi, 2011). However, no direct role for Th17 cells in
cancer induced bone disease has been reported so far. In line with
this, IL-17F, which shows 50% homology with IL-17A and shares
its receptor, was produced in high levels in the 4T1 preclinical
tumor model, but found not to be necessary for the development
of pre-metastatic bone disease (Monteiro et al., 2013).
The effects of conventional T cells on osteoclastogenesis are
normally suppressed by regulatory T (Treg) cells. These cells are
able to inhibit osteoclast development and function via the release
of tumor growth factor-β (TGF-β), IL-10 (Kim et al., 2007b;
Kelchtermans et al., 2009) and expression of CTLA-4 (Zaiss
et al., 2007). In addition to their suppressive capabilities, tumor-
infiltrating Treg cells have also been described to express RANKL
(Tan et al., 2011). As a consequence, the effect of Treg cells on
osteoclastogenesis depends on the balance between positive and
negative factors within the tumor microenvironment.
Myeloid-derived suppressor cells (MDSCs) are a
heterogeneous population of immature myeloid cells, which
are capable of potently suppressing the anti-tumor functions
of conventional T lymphocytes (Gabrilovich and Nagaraj,
2009). It has been shown that MDSCs derived from the
tumor microenvironment can differentiate into bone-resorbing
osteoclasts under tissue culture conditions (Sawant et al.,
2013) and MDSCs from tumor-bearing mice have increased
osteoclastogenic potential (Zhuang et al., 2012).
Tumor-associated macrophages (TAMs) are a predominant
white blood cell subset both in the bone and tumor
microenvironment, which can influence tumor development,
proliferation, growth, survival, and metastasis formation.
Macrophages classically have been divided into proinflammatory
M1 and anti-inflammatory M2 subsets (Mosser and Edwards,
2008). When activated, M1 macrophages secrete high levels of
proinflammatory cytokines and participate in the elimination of
tumor cells (Gabrilovich et al., 2012). However, M2 macrophages
are characterized by high expression of mannose receptors,
scavenger receptors and IL-1Ra (Zhang et al., 2012), and
are also often found in human solid tumors. Activated M2
macrophages generate high levels of IL-10 and TGF-β, which
can suppress CD4+ and CD8+ conventional T cells (Biswas and
Mantovani, 2010). In preclinical studies, where tumor-associated
macrophages were depleted using clodronate liposomes,
reduced number of bone metastatic lesions were detected
(Hiraoka et al., 2008).
ROLE OF RANKL SIGNALING IN
OSTEOCLASTS AND BONE METASTASIS
FORMATION
Receptor activator of NF-κB ligand (RANKL) belongs to the
tumor necrosis factor (TNF) superfamily of cytokines and
it is expressed by monocytes, T and B cells, dendritic cells
and osteoclastogenesis-supporting cells, such as osteoblasts and
synovial fibroblasts (Caetano-Lopes et al., 2009). Parathyroid
hormone, 1,25-dihydroxy-cholecalciferol (active vitamin D3)
and prostaglandins can promote the secretion of RANKL by
osteoblasts and other stromal cellular elements (Takayanagi,
2007). CD4+ conventional and regulatory T lymphocytes are
also able to provide RANKL in membrane-bound form as well
as release it in a soluble form (Wong et al., 1997). TNF-α, IL-
1, IL-6 and IL-17 cytokines can increase RANKL expression on
osteoclastogenesis-supporting cells, thereby stimulating RANKL
signaling (Takayanagi, 2007). Osteoprotegerin (OPG), expressed
by osteoblasts and other stromal cells, is a soluble decoy
receptor for RANKL capable of inhibiting RANK signaling
(Simonet et al., 1997).
The RANKL receptor, RANK, is highly expressed by
preosteoclast. RANKL binding to RANK leads to receptor
trimerization and activation of the adapter protein TRAF6,
which further stimulates transcription factor NF-κB and
members of the mitogen-activated protein kinase (MAPK)
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Győri and Mócsai Osteoclast Signaling in Bone Metastasis
family (Takayanagi, 2010) as shown on Figure 1. Nuclear
factor of activated T-cell cytoplasmic 1 (NFATc1), the master
regulator of osteoclast differentiation, is also activated by RANK
receptor signaling (Takayanagi, 2010). NFATc1 translocates to
the nucleus and then amplifies its own expression resulting in
strong induction of NFATc1 expression (Asagiri et al., 2005).
Generation of calcium signal and calcineurin activation are also
important for NFATc1 induction. NFATc1 together with activator
protein 1 (AP-1) and microphthalmia-associated transcription
factor (MITF) induce then the expression of osteoclast-specific
genes encoding for tartrate-resistant acid phosphatase (TRAP),
cathepsin K (CTSK) and the β3 integrin (Takayanagi, 2007).
The expression of NFATc1 in osteoclasts and their precursors
is also regulated on the epigenetic level. An important step
in the differentiation of osteoclasts occurs at the NFATc1
promoter when the histone methylation changes from
H3K4me3/H3K27me3 to H3K4me3 (Yasui et al., 2011). A histone
demethylase, Jmjd3 converts the bivalent H3K4/H3K27
trimethylation to monovalent H3K4me3 in preosteoclasts
following RANKL stimulation, leading to increased osteoclast
differentiation as well (Yasui et al., 2011). On the other hand,
NFATc1 expression can also be inhibited by other transcription
factors such as Interferon regulatory factor 8 (IRF-8) (Zhao et al.,
2009), bZIP motif containing transcription factor MafB (Kim
et al., 2007a), B-cell lymphoma 6 (Bcl-6) (Miyauchi et al., 2010),
and Leukemia/lymphoma related factor (LRF) (Tsuji-Takechi
et al., 2012). The expression of those transcription factors
decrease during osteoclast differentiation, which is mediated by
the DNA methyl-transferase 3A (Dnmt3A) (Nishikawa et al.,
2015). Furthermore, the B lymphocyte-induced maturation
protein (Blimp) was shown to be able to inhibit IRF-8, MafB, Bcl-
6 and LRZ transcription factors, leading to upregulated NFATc1
expression and enhanced osteoclastogenesis (Nishikawa et al.,
2010). In line with this, Blimp1-deficient mice exhibit increased
bone mass and osteopetrotic disease (Nishikawa et al., 2010).
Cancer cells enhance osteoclast-driven osteolysis via several
different mechanisms. Upregulation of the expression of RANKL
on osteoclastogenesis-supporting cells, downregulation of OPG
expression or increased secretion of factors activating RANK
receptor signaling have all been described in the context of
breast cancer bone metastases (Kearns et al., 2008). Prostate
tumor cells can even express RANKL themselves (Brown et al.,
2001). Further, secretion of RANKL has also been described
by multiple myeloma cells (Farrugia et al., 2003; Sezer et al.,
2003). While breast tumors do not upregulate RANKL (Thomas
et al., 1999), those cells can eventually induce the expression
of RANKL on osteoblasts (Kitazawa and Kitazawa, 2002) and
other osteoclastogenesis-supporting cells via the production
and release of PTHrP (Mancino et al., 2001). RANK receptor
expression by melanoma, breast and prostate cancer cell lines
has also been described (Jones et al., 2006), and involved in
the autocrine effect of tumor cell-derived RANKL on promoting
cancer cell migration. Downregulation of OPG secretion has
been found to be characteristic for breast cancer and multiple
myeloma cells (Thomas et al., 1999; Giuliani et al., 2001).
As a consequence, the RANKL-OPG balance is disturbed
within the bone microenvironment in favor of supporting
osteoclast-induced osteolysis and bone metastasis formation
(Grimaud et al., 2003). Denosumab, a monoclonal antibody
raised against RANKL, demonstrated efficacy in preventing
tumor-induced bone loss in patients with skeletal metastasis
(Choi et al., 2009).
It has also been reported that certain tumor cell-derived
soluble factors are able to induce osteoclastogenesis independent
of RANKL. Secretion of lysyl oxidase (LOX) from primary breast
carcinoma cells induced osteoclast differentiation and osteolytic
skeletal lesion formation in animal tumor models (Cox et al.,
2015). However, LOX failed to substitute for RANKL when
Tnfrsf11a (RANK)-deficient bone marrow cells were treated with
recombinant LOX protein in subsequent experiments (Tsukasaki
et al., 2017). Similarly, initial data indicated that Tnfrsf11a−/−
primary bone marrow cells were capable to differentiate into
osteoclasts under TNFα stimulation, when RBP-J transcription
factor was deleted in the progenitors (Kim et al., 2005; Zhao et al.,
2012). However, RBP-J deletion in mice did not exhibit obvious
defects in bone phenotype, suggesting that RBP-J plays a minor
role in osteoclast development under physiological conditions
(Zhao et al., 2012). Although there have been other factors
indicated to induce RANKL-independent osteoclastogenesis,
they may be able to promote osteoclast differentiation only under
certain conditions and cannot completely substitute for RANK
ligand (Tanaka, 2017). Identifying the precise role of these factors
in osteoclasts within the solid tumor microenvironment requires
further investigation.
ROLE OF CSF-1 SIGNALING IN
OSTEOCLASTS AND BONE METASTASIS
FORMATION
Another key osteoclastogenic cytokine that governs
osteoclastogenesis is CSF-1 (or macrophage-colony stimulating
factor, M-CSF). CSF-1 is a polypeptide growth factor that binds
to its plasmamembrane receptor (CSF-1R) encoded by the c-fms
gene (Stanley et al., 1983). CSF-1 is essential for the development
and survival of preosteoclasts (Ross and Teitelbaum, 2005).
CSF-1 was originally identified as a regulator of macrophages
and their bone marrow precursors (Stanley et al., 1983). As
shown on Figure 1, once CSF-1 binds to its transmembrane
receptor CSF-1R, it induces tyrosine phosphorylation of the
cytoplasmic domain of the receptor (Pixley and Stanley, 2004).
Then Src homology 2 domain (SH2)-bearing adapter molecules
(such as Grb2) are recruited to the phosphorylated tyrosine
residues and initiate different signaling cascades (including
the MAP-kinase cascade) that lead to cell proliferation and
differentiation (Pixley and Stanley, 2004). CSF-1 is also known to
induce cytoskeletal rearrangement in osteoclasts by activation of
the c-Src and phosphoinositide 3-kinases (Nakamura et al., 1995;
Insogna et al., 1997; Pilkington et al., 1998). CSF-1 deficient mice
are osteopetrotic (Wiktor-Jedrzejczak et al., 1990).
When considering CSF-1R and RANK-driven non-
pathological osteoclastogenesis, it is important to note, that
apart from TGF-β, the cytokine IL-1 is supposed to be released
from the bone as an autocrine factor. It has been described,
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FIGURE 1 | Summary of osteoclast differentiation induced by integration of CSF-1R, RANK, immunoreceptor-like and integrin receptor signaling. CSF-1 and its
receptor CSF-1R activate the MAPK cascade pathway leading to the survival and proliferation of preosteoclasts. RANKL and its receptor RANK transduce signals
via the adaptor molecule TRAF6, which activates the NF-κB and MAPK pathways leading to the differentiation of osteoclasts. The expression of the master regulator
of osteoclastogenesis, NFATc1, is driven by NF-κB and NFATc1. The activation of NFATc1 is also regulated by the costimulatory signaling pathways, where FcRγ,
DAP12 and their associating partners (OSCAR and TREM2, respectively) recruit Syk, which further activates PLCγ2, resulting in the activation of calcium signaling.
The calcium signaling activates then calcineurin, which in turn promotes NFATc1 expression. The calcium signal also induces Vav3 activation involved in αvβ3 integrin
signaling, which leads to cytoskeletal reorganization and osteoclastic bone resorption.
that osteoclast precursor interaction with bone matrix (but not
plastic surface) can induce osteoclast formation directly by an
interleukin-1-mediated autocrine mechanism in the presence of
CSF-1 (Yao et al., 2008; De Vries et al., 2015).
In addition to its physiological role in myeloid cells,
increased expression of CSF-1 has been detected in breast,
colorectal, ovarian and uterine cancers, where the extent of
its expression correlates with poor prognosis (Kacinski, 1995;
Smith et al., 1995). Furthermore, in human breast carcinomas,
overexpression of CSF-1 and its receptor positively correlates
with high grade invasiveness (Kacinski, 1995; Smith et al., 1995).
Importantly, a strong correlation of CSF-1 expression with CSF-
1R-positive tumor-associated macrophage infiltration has also
been detected in human carcinomas (Tang et al., 1990; Scholl
et al., 1994). We recently demonstrated that pharmacological
inhibition or genetic ablation of CSF1 in cancer cells reduces the
accumulation of immunosuppressive CSF-1R+ tumor-associated
macrophages and increases CD8+ T cell attack on tumors
(Győri et al., 2018).
In line with this, it is highly likely that certain tumor cells
capable of forming osteolytic bone metastasis recruit not only
tumor-associated macrophages, but monocytes/osteoclast
precursors via the secretion of CSF-1 into the tumor
microenvironment. Furthermore, tumor cell-derived CSF-1
can also enhance the maturation of those precursors to bone-
resorbing osteoclasts in the presence of an osteoclastogenic
milieu. As a consequence, pharmacological blockade of
CSF-1 might offer benefits for patients with osteolytic bone
metastases and CSF-1 inhibitors are being evaluated in
clinical trials. PLX3397, an orally available CSF-1R inhibitor
is currently being administered in clinical trials and early
data suggested good tolerability and beneficial effects (Ries
et al., 2015). It has also been described, that CSF-1R and αvβ3
integrins collaborate during osteoclast differentiation via shared
activation of downstream signaling pathways (Faccio et al., 2003;
Ross and Teitelbaum, 2005).
ROLE OF INTEGRIN SIGNALING IN
OSTEOCLASTS AND BONE METASTASIS
FORMATION
Integrins are heterodimeric transmembrane proteins that
facilitate cell-cell and cell-matrix interactions (Schwartz et al.,
1995). Integrins can activate many intracellular signaling
pathways and induce the proliferation, survival, and cytoskeletal
rearrangements of the target cells (Hynes, 1992). So far 8 beta
and 18 alpha integrin subunits have been described, which can
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combine into 24 unique heterodimers within the different cell
types, each of those characterized by different ligand binding
characteristics, signaling and regulatory mechanisms (Hynes,
2002). Integrin heterodimers can be activated by conformational
changes in their extracellular domains. When inactive, integrin
dimers are found in a closed conformation within the cell
membrane. Upon activation through the cytoplasmic domains,
the α and β cytoplasmic and transmembrane regions become
separated resulting in the unfolding of the extracellular ligand
binding domain (inside-out signaling) (Shattil et al., 2010). This
open conformation then promotes extracellular ligand binding
and initiates integrin-driven intracellular signaling pathways
(outside-in signaling) (Qin et al., 2004).
Integrins play critical roles on both tumor cells and osteoclasts
in promoting bone metastasis formation. During the process of
bone resorption, mature osteoclasts attach to the bone surface,
generate an actin ring mediated sealing zone and then secrete
hydrochloric acid and enzymes to lyse the underlying bone
matrix. All of these steps at least in part are regulated by integrin
heterodimers located on the surface of osteoclasts (Teitelbaum
and Ross, 2003). Different integrins are involved in the binding
of osteoclasts to the bone, including αvβ3, αvβ5, and α2β1, of
which, αvβ3 is the dominant integrin on osteoclasts (Ross and
Teitelbaum, 2005; Novack and Teitelbaum, 2008; Ross et al.,
1993). αvβ3 integrins are responsible for mediating osteoclast-
bone matrix recognition and subsequent attachment to the bone
surface (Ross et al., 1993). αvβ3 integrin signaling is essential for
osteoclast spreading and to create the characteristic ruffled border
of the plasmamembrane for subsequent resorption (Faccio et al.,
2003; McHugh, 2000). Furthermore, osteopontin binding to αvβ3
induce podosome formation and cytoskeletal rearrangement
(Miyauchi et al., 1991). Additional studies identified further
downstream signaling effector molecules such as Vav, a critical
regulator of osteoclast differentiation and actin ring formation
(Faccio et al., 2005). As a consequence, mice with genetic
inactivation of β3 integrin (β3−/−) have defective osteoclast
function (McHugh, 2000) and are protected from cancer cell-
induced bone loss (Bakewell et al., 2003). αvβ3 integrins are
also critical for the activation of c-Src which is a key signaling
molecule in osteoclast spreading and cytoskeletal reorganization
(Zhang et al., 2000; Faccio et al., 2003).
Cancer cells display altered integrin expression and signaling,
allowing them to colonize new tissues by escaping from cell–
cell and cell–matrix connections. Maintaining adhesion to the
extracellular matrix via integrins is key to cell survival (Frisch
and Screaton, 2001). Disruption of cell–cell or cell–matrix
interactions lead to loss of survival signals and non-transformed
cells which are anchorage-dependent undergo a form of
programmed cell death called anoikis (Frisch and Screaton,
2001). Under physiological conditions, this form of apoptosis
assures that isolated cells are not able to migrate to inappropriate
locations (Frisch and Screaton, 2001). Metastatic cancer cells that
can resist anoikis utilize several different mechanisms in order to
be able to settle in a novel microenvironment. These mechanisms
include altered integrin expression (Bissell and Radisky, 2001),
activation of integrin signaling cascade downstream molecules
such as focal adhesion (Frisch et al., 1996) and c-Src kinases
(Shain et al., 2002), EGFR (Demers et al., 2009), as well
as suppression of apoptotic pathways (Simpson et al., 2008).
Expression of αvβ3 integrin is elevated on human breast cancer
bone metastases (Zhao et al., 2007), and ectopic overexpression
of the β3 subunit on breast cancer cells has been demonstrated to
enhance tumor establishment in bone (Sloan et al., 2006).
ROLE OF c-Src KINASE IN
OSTEOCLASTS AND BONE METASTASIS
FORMATION
The non-receptor tyrosine kinase, c-Src is a key signaling
molecule in bone metabolism and plays an important role
in the regulation of growth, survival, proliferation, adhesion
and motility (Brunton and Frame, 2008). Preclinical studies
demonstrated an important role for Src-family kinases in
osteoclast-mediated bone resorption (Horne et al., 1992). Mature
osteoclasts express high levels of c-Src (Miyazaki et al., 2004).
Pharmacological inhibition of c-Src kinase-activity decreased
preosteoclast migration and inhibited the subsequent formation
of resorption pits in in vitro studies (de Vries et al., 2009). Mice
with genetic inactivation of the c-Src gene exhibit osteopetrosis,
a severe disease that makes bones abnormally dense and prone
to fractures (Soriano et al., 1991). Since c-Src-deficient mice had
normal osteoclast numbers, the osteopetrotic phenotype is rather
due to a failure in osteoclast function (Soriano et al., 1991).
Further, Src-deficient mature osteoclasts fail to form actin rings
and sealing zones (Boyce et al., 1992).
Besides regulating cytoskeletal rearrangement and ruffled
border formation, Src-family kinases are also present at vesicular
membranes, where they are required for the secretion of
hydrochloric acid and bone-degrading enzymes (Furuyama
and Fujisawa, 2000; Edwards et al., 2006). Among Src-family
kinase binding partners, Tks5 has been shown to mediate
podosome formation and cell-cell fusion in osteoclasts (Oikawa
et al., 2012). Tks5, which has been originally described as
a regulator of invadopodia formation in tumor cells, was
reported to be phosphorylated on tyrosine residues in a c-Src-
dependent manner within osteoclasts (Oikawa et al., 2012).
Furthermore, it was also shown that co-culturing malignant
melanoma cells with osteoclasts promoted the formation of
melanoma-osteoclast hybrid cells (Oikawa et al., 2012). Fusion
of osteoclasts with cancer cells can contribute to increased bone
resorption activity, secretion of chemokines promoting osteolytic
bone metastasis formation and even the evasion of immune
surveillance (Oikawa et al., 2012).
An elevated level of activity of c-Src is suggested to be
linked to cancer progression and a large body of evidence
suggests that Src-family kinase has a critical role in cancer
growth and invasion (Thomas and Brugge, 1997). Further,
Src expression positively correlates with the metastatic spread
of cancer cells (Boyer and Poupon, 2002). Importantly,
correlation was also observed between tumor cell colonization
in bone and Src kinase activity (Myoui et al., 2003). Increased
Src family kinase activity fueled tumor cell growth and
enhanced parathyroid hormone related peptide (PTHrP) release
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within bone metastases (Myoui et al., 2003). Small-molecule
kinase inhibitors are emerging new therapeutics in diseases
with pathological bone loss and have potential for the
treatment of bone metastases as well. Preclinical studies with
therapeutic Src inhibitors (dasatinib, saracatinib, and bosutinib)
demonstrated anti-tumor and anti-osteoclast effects, as well
as clinical studies provided evidence that Src-family kinase
inhibitors might be beneficial for patients with refractory disease
(Boyce and Xing, 2011).
ROLE OF IMMUNORECEPTOR-LIKE
SIGNALING IN OSTEOCLASTS AND
BONE METASTASIS FORMATION
Classical immunoreceptors, such as T and B cell receptors
(TCR, BCR, respectively) as well as Fc-receptors (FcR) use a
common signaling machinery within the innate and adaptive
immune systems. Firstly, when ligand binds to the classical
immunoreceptor, tyrosine residues within the immunoreceptor
tyrosine-based activation motifs (ITAMs) are phosphorylated by
Src kinases as shown on Figure 1. This then results in the SH2-
domain dependent recruitment of the spleen tyrosine kinase
(Syk) (Fodor et al., 2006). Src and Syk non-receptor tyrosine
kinases then activate downstream effector molecules such as
the phospholipase Cγ2 (PLCγ2) and phosphoinositide 3-kinase
(PI3K) isoforms. We and others recently recognized that this
classical immunoreceptor-like signaling mechanism is present in
a range of non-lymphoid cell types (e.g., osteoclasts) too (Koga
et al., 2004; Mócsai et al., 2004).
Osteoclasts carry at least two ITAM sequence-containing
adapter molecules, namely the DAP12 and the FcR γ-chain
(FcRγ). These proteins likely work together with adhesion
receptors OSCAR and TREM2 on osteoclasts (Koga et al., 2004).
Deletion of DAP12 and TREM2 in mice results in failure of
osteoclast differentiation and function (Paloneva et al., 2003;
Humphrey et al., 2004). On the other hand, TREM2 and
DAP12 deficient mice are not osteopetrotic, which indicates
that osteoclastogenesis can proceed through a mechanism
that requires the other ITAM-bearing molecule FcR γ-chain.
FcRγ, may be able to compensate for the lack of DAP12,
since double mutant mice for FcRγ and DAP12 are severely
osteopetrotic (Koga et al., 2004; Mócsai et al., 2004). These ITAM-
bearing co-receptors most likely mediate osteoclast-osteoblast
and osteoclast-bone matrix interactions together with integrin
adhesion receptors (Koga et al., 2004; Mócsai et al., 2004).
More recently, paired immunoglobulin-like receptor-A (PIR-A)
and osteoclast-associated receptor (OSCAR) has been shown to
associate with the FcRγ-chain (FcRγ), while DAP12 interaction
with signal regulatory protein β1 (SIRPβ1), sialic acid-binding
immunoglobulin-like lectin 15 (Siglec-15) and myeloid DAP12-
associating lectin (MDL)-1 besides TREM2 has also been
reported (Koga et al., 2004; Mócsai et al., 2004; Joyce-Shaikh et al.,
2010; Kameda et al., 2013; Negishi-Koga et al., 2015).
As discussed before, β3 integrin ligation leads to activation
of Src-family kinases and a non-receptor kinase, Syk. The Syk
tyrosine kinase is required for the differentiation and function of
osteoclasts as well (Mócsai et al., 2004). Activation of Syk requires
the presence of ITAM-bearing adapters, DAP12 and FcRγ-chain
in the osteoclast (Mócsai et al., 2004). We recently showed,
that osteoclast-specific genetic inactivation of Syk also leads to
elevated bone volume in mice (Csete et al., 2019). Syk inhibitors
(like fostamatinib) has shown promising effects in rheumatoid
arthritis and may also provide significant bone protection in
a tumor-associated environment (Mócsai et al., 2010). The
osteopetrotic phenotype (Soriano et al., 1991) and defective
osteoclastogenesis in the Src-deficient mice indicates that Src-
family kinases might be also required for the phosphorylation
of DAP12 and FcRγ in osteoclasts (Lowe et al., 1993). Syk
then promotes the formation of the Bruton’s tyrosine kinase
(Btk)/B cell linker protein (BLNK)/SH2 domain-containing
leukocyte protein of 76 kDa (SLP76) complex, which activates
the phospholipase Cγ2 (PLCγ2) enzyme. PLCγ2 cleaves the
plasmamembrane phosphatidylinositol 4,5-bisphosphate (PIP2)
into inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG)
(Feng et al., 2012). We and others showed that PLCγ2 is
needed for the differentiation and function of osteoclasts
and PLCγ2−/− mice have increased bone mass (Mao et al.,
2006; Chen et al., 2008; Epple et al., 2008; Kertész et al.,
2012). IP3 generated by PLCγ2 then binds to its receptor,
which in turn induces the release of calcium ions from
the sarco/endoplasmic reticulum (SR/ER). Sarco/endoplasmic
reticulum calcium ATPase 2 (SERCA2) re-uptakes the calcium
into SR/ER (Yang et al., 2009). Repetitive influx and efflux of
calcium ions results in calcium oscillations within the cytoplasm
of the osteoclast. Calcium oscillations activate calcineurin,
which leads to the dephosphorylation of the master regulator
of osteoclastogenesis, NFATc1, enabling its autoamplification
and entry to the nucleus. Calcium signaling can also induce
c-Fos transcription factor via Calcium/calmodulin dependent
kinase (CAMK) IV and cAMP response-element binding protein
(CREB) pathways (Sato et al., 2006a). Further, transmembrane
protein 64 (Tmem64) has been reported to be essential for the
function of SERCA2 (Kim et al., 2013), while the transmembrane
protein 178 (Tmem178) was shown to be required to suppress
the excessive efflux of calcium in a PLCγ2-dependent manner
(Decker et al., 2015). Accordingly, mice deficient in DAP12/FcRγ,
SERCA2 and Tmem64 are osteopetrotic and exhibit defective
calcium oscillations (Yang et al., 2009; Kim et al., 2013). On the
other hand, lack of Tmem178 in mice results in an osteopenic
phenotype with increased amplitude of calcium oscillations
(Decker et al., 2015).
Immunoreceptor-like signaling has been implicated in
metastatic spread and homing of cancer cells to distant organs
such as the bone. TREM2 was found to be upregulated on
peripheral blood monocytes in tumor-bearing hosts and elevated
expression levels in pulmonary macrophages correlated with
high pathological stage of lung adenocarcinomas (Yao et al.,
2016). Further, DAP12 expression in colorectal cancer cells was
associated with higher tumor grade (Shabo et al., 2013) and Syk
is also frequently upregulated in recurrent ovarian carcinomas
metastasizing to the bone (Yu et al., 2019). On the other hand,
while PLCγ2 has been implicated in the proliferation and
migration of several human cancers (Feng et al., 2012), its genetic
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deletion in mice resulted in increased tumor growth (Zhang et al.,
2011). Interestingly, it has been shown that PLCγ2−/− mice
exhibit increased tumor mass in the bone, despite the decreased
osteoclast numbers. Although PLCγ2 is not needed for T cell
receptor signaling, altered CD8+ T cell activation was observed
in PLCγ2−/− tumor-bearing mice (Zhang et al., 2011). Recent
evidence indicated that downregulation of PLCγ2 signaling
results in the accumulation of immunosuppressive MDSCs in
tumor-bearing mice instead (Capietto et al., 2013). This study
highlights the role of a permissive immune phenotype and
microenvironment as the requirement for osteoclast-mediated
promotion of tumor growth and bone metastasis.
ROLE OF EPHRINS AND SEMAPHORINS
IN OSTEOCLASTS AND BONE
METASTASIS FORMATION
Cell–cell interactions are critical for normal bone homeostasis.
Ephrins and Semaphorins are known to be expressed in several
cell types and regulate intercellular communication. Eph tyrosine
kinase receptors and Ephrin ligands mediate interactions between
bone cells through a bidirectional signaling. These membrane-
bound proteins have been demonstrated to play important roles
in osteoblasts and osteoclasts (Edwards and Mundy, 2008).
EphrinB2 has been shown to be regulated by PTH and PTHrP in
osteoblasts, while the role of EphrinA4 in modulating osteoclast
activity via β3-integrin signaling has recently been identified
(Stiffel et al., 2014). The altered expression of Eph tyrosine
kinase receptors and ephrins has also been demonstrated in
several human cancers, e.g., EphrinA2 levels were detected to
be elevated in late-stage and bone metastatic prostate cancers
(Lin et al., 2012).
Semaphorins play critical roles in the immune system, organ
and tumor development. It has been shown that Semaphorin
3A (Sema3A) and its receptor neuropilin-1 (Nrp1) suppress
osteoclast differentiation and protect mice from excessive bone
loss (Hayashi et al., 2012). The Semaphorin 6D (Sema6D),
which associate with TREM2/DAP12 via its receptor plexin-A1
(PlxnA1), on the other hand, promoted osteoclast differentiation
and function (Takegahara et al., 2006). Semaphorins were also
shown to contribute to the pathogenesis of cancer, including
the regulation of epithelial-mesenchymal transitions and stem
cell properties (Lontos et al., 2018). In the process of bone
metastasis formation Semaphorin 4D, a coupling factor expressed
on osteoclasts that inhibits osteoblast differentiation, has recently
been implicated (Lontos et al., 2018).
ROLE OF PHOSPHOINOSITIDE
3-KINASES IN OSTEOCLASTS AND
BONE METASTASIS FORMATION
Phosphoinositide 3-kinases (PI3Ks) generate 3-phosphoinositide
lipids in cell membranes and play important roles in key
biological functions including cellular proliferation, survival,
cytoskeletal reorganization, migration, metabolism and vesicular
trafficking (Vanhaesebroeck et al., 2012; Hawkins and Stephens,
2015). PI3Ks are subgrouped into three unique classes of which
the Class I. PI3K family comprise of PI3Kα, PI3Kβ, PI3Kγ, and
PI3Kδ (Hawkins et al., 2006; Vanhaesebroeck et al., 2010). PI3Kα
and PI3Kβ are ubiquitously expressed, while the PI3Kγ and
PI3Kδ isoforms are mainly restricted to hematopoietic lineages,
e.g., white blood cells (Okkenhaug, 2013). 3-phosphoinositide
lipids such as PIP3 can initiate a number of downstream
signaling pathways and activate effector molecules, like the
3-phosphoinositide dependent protein kinase-1 (PDK1), Ser/Thr
kinase Akt (or protein kinase B) and the mammalian target of
rapamycin complex 1 (mTORC1) (Hawkins et al., 2006).
PI3-kinases are central downstream effectors of the RANK,
CSF-1 and αvβ3 integrin receptors in osteoclasts. Activation
of Class I. PI3Ks downstream of those receptors results in
the generation of PIP3 from PIP2. Class I.A PI3Ks (PI3Kα,
PI3Kβ, PI3Kδ) are designated based on catalytic subunits p110α,
p110β, and p110δ, which associate with regulatory subunits p85α,
p85β, and p55γ. The sole Class I.B member PI3Kγ consists
of catalytic subunit p110γ and regulatory subunit p101 or
p84. Mice lacking p110α exhibit embryonic lethality (Bi et al.,
1999), while p110γ mutant mice are viable but show defects in
immune cell proliferation and function (Sasaki et al., 2000). Mice
knockout for the p85α/β subunit showed impaired osteoclast
differentiation and ruffled border formation (Munugalavadla
et al., 2008; Shinohara et al., 2012). These data indicated that PIP3
is a strong inducer of osteoclast differentiation and PI3-kinases
might play an important role in regulating osteoclastogenesis.
We and others have shown that Class I. PI3Ks play a
critical role in osteoclasts and could be potential therapeutic
targets in bone metastases (Shinohara et al., 2012; Shugg et al.,
2013; Győri et al., 2014). Previous studies using non-selective
PI3K inhibitors (such as wortmannin) indicated a role for
PI3-kinases in osteoclastogenesis (Hall et al., 1995; Nakamura
et al., 1995; Sato et al., 1996). Using pharmacological and
genetic approaches we demonstrated that PI3Kβ is important
for normal osteoclast differentiation and function (Győri et al.,
2014). PI3Kβ−/− mice had increased bone mass and PI3Kβ−/−
osteoclasts displayed altered morphology in vivo (Győri et al.,
2014). Further, PI3Kβ−/− osteoclasts were unable to form actin
rings and to release intracellular vesicles and cathepsin K (Győri
et al., 2014). In addition to this, the PI3Kδ isoform, which
is mainly expressed in hematopoietic cells, has been found to
be an attractive target for anti-resorptive agents since recent
data indicated that PI3Kδ regulates osteoclast cytoskeleton and
resorptive activity (Shugg et al., 2013).
Class I. PI3Ks are often mutated in human cancers (Fruman
and Rommel, 2014). Aberrant activation and amplification
of PI3Kα is one of the most frequently observed mutations
associated with malignant transformation (Samuels et al., 2005;
Thorpe et al., 2015). Oncogenic mutations have also been
detected in PI3Kβ, but rarely in PI3Kγ and PI3Kδ (Hill et al.,
2010; Dbouk et al., 2013). An elevated level of activity of PI3Kδ
was found in non-hematopoietic cell types, including those of
breast and melanocytic origin (Sawyer et al., 2003). Further,
PI3K downstream targets are also often seen abnormally activated
in human malignancies. Overexpression of Akt/PKB has been
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observed in a wide range of solid tumors, including breast,
ovarian and prostate carcinomas (Scheid and Woodgett, 2001;
Vivanco and Sawyers, 2002). The recognition of the tumor
suppressor PTEN, a phosphatase for 3-phosphoinositide lipids,
proved to be an indicator of aberrant PI3K signal transduction
in cancer (Cantley and Neel, 1999). Deletions and mutations
in the PTEN gene also lead to the accumulation of PI3K
lipid products, which is observed in many human tumors
(Di Cristofano and Pandolfi, 2000).
There is substantial interest in the pharmaceutical industry to
develop PI3K inhibitors for the treatment of human cancers. To
avoid the serious side effects of pan–Class (I) PI3K drugs affecting
glucose homeostasis (Busaidy et al., 2012), administration of
isoform-selective PI3K inhibitors below their maximum tolerated
dose, most likely in combination may be beneficial. Based on
its role in the tumor microenvironment PI3Kβ and/or PI3Kδ
may be suitable therapeutic targets for bone metastases with
tumor-induced osteolysis.
ROLE OF MICRORNAs AND
EXTRACELLULAR VESICLES IN
OSTEOCLASTS AND BONE METASTASIS
FORMATION
MicroRNAs are non-coding RNAs of approximately 20–22
nucleotides in length which regulate critical cellular processes
including proliferation, differentiation, and survival. Recent data
indicated that microRNAs are involved in tumorigenesis and
osteolytic bone metastasis formation as well. Various tumor-
cell derived mature microRNAs were implicated in regulating
osteoclast differentiation. miR-223 was shown to regulate the
level of the CSF1 receptor in preosteoclasts (Sugatani and
Hruska, 2007), while miR-503 targets RANK (Chen et al.,
2014). Further, miR-29 promotes murine osteoclastogenesis by
regulating osteoclast commitment and migration (Franceschetti
et al., 2013). On the other hand, miR-124 was detected to
suppress transcription factor NFATc1 during osteoclastogenesis
(Lee et al., 2013), while miR-155 represses MITF and PU.1
transcription factors (Mann et al., 2010). It has been reported that
administration of miR-141 and miR-219 results in a significant
drop in the number of bone-resorbing osteoclasts in vivo and
tumor burden in breast carcinoma-bearing mice (Ell et al.,
2013). Similarly, miR-33a suppressed bone metastasis formation
by targeting PTHrP and altering the RANKL/OPG ratios in
osteoblasts (Kuo et al., 2013).
MicroRNAs were recently revealed to be present in
extracellular vesicles (Valadi et al., 2007). Extracellular vesicles
are lipid bilayer coated vesicles ranging from approximately
50 to 5000 nm in diameter. Three main types of extracellular
vesicles exist: microvesicles, exosomes and apoptotic bodies
(Marton et al., 2017). MicroRNA-containing extracellular vesicle
secretion depends on various different factors. Numerous studies
suggested the involvement of extracellular vesicles secreted by
tumor cells in the development of osteolytic bone metastases
(Kagiya, 2015). Exosomal miR-21, miR-210 and miR-378 were
found to be important for regulating osteoclast differentiation
(Kagiya, 2015). Further, miR-16 and miR-378 were detected to be
FIGURE 2 | Schematic representation of physiological and pathological osteoclast activation during bone metastasis formation and key signaling molecules within
the solid tumor microenvironment from a therapeutic aspect. Osteoblast-derived cytokines and interactions with the bone matrix lead to physiological osteoclast
activation via CSF1, RANK, costimulatory and β3 integrin receptors. “Osteotropic” tumor cell recruited regulatory T cells (Tregs) and myeloid derived suppressor cells
(MDSC) inhibit conventional T cells (Tconv) and promote cancer cell-induced pathological osteoclast activation via PI3Kβ, PI3Kδ, c-Src, and Syk.
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higher in the serum of metastatic breast cancer patients (Arroyo
et al., 2011; Ell et al., 2013). Accordingly, extracellular vesicles play
an important role in intercellular communication via the transfer
of not only microRNAs and proteins, but also bioactive lipids
such as PIP3 generated by phosphoinositide 3-kinases.
THERAPEUTIC ASPECTS AND FUTURE
PERSPECTIVES
Tight coupling between bone formation and resorption is
essential for bone remodeling. Disruption of this balance can
lead to skeletal disorders. Skeletal metastatic disease is a severe
consequence of tumor cell dissemination from primary cancer
sites, and significantly decreases wellbeing and life expectancy in
patients. The bone is a major target for tumor metastasis as it
provides a unique environment, which promotes solid cancer cell
dissemination (Weilbaecher et al., 2011). The balance between
bone-forming osteoblasts and bone-resorbing osteoclasts is
altered by bone metastasis formation (Mundy, 2002). Cancer
cell invasion into the bone is associated with the activation
of osteoclasts. Osteoclast-mediated osteolysis then leads to the
release of cytokines and growth factors deposited in the bone
matrix. This further fuels tumor growth and dissemination
within the tissue (“vicious cycle” of bone metastasis formation)
(Faccio, 2011).
RANK ligand, an important osteoclastogenic factor, is
expressed by osteoblasts and cancer cells (Kearns et al.,
2008). PTHrP secreted by tumor cells indirectly promotes
osteoclastogenesis-supporting cells to express RANK ligand
(Suva et al., 1987; Mancino et al., 2001). CSF-1, necessary for
the development of preosteoclast to osteoclasts, is also derived
from cancer cells (Stanley et al., 1983; Smith et al., 1995).
Once bone metastasis is established, cancer cells recruit other
tumor-associated cells, including fibroblasts and immune cells
which secrete cytokines (such as IL-17, IL-1, IL-6, and TNF-α)
that increase RANK ligand expression (Mancino et al., 2001;
Kitazawa and Kitazawa, 2002). Integrin and immunoreceptor-
like signaling leads to the activation of key effector molecules,
such as Src-family kinases (Myoui et al., 2003), Syk non-receptor
tyrosine kinase (Mócsai et al., 2010) and phosphoinositide
3-kinases (PI3Ks), which further enhance osteoclast activity
and subsequent bone destruction (Di Cristofano and Pandolfi,
2000). Summary of the mechanisms of osteoclast activation
during cancer cell-induced osteolysis as well as the key osteoclast
signaling molecules are shown on Figure 2.
Better understanding of the molecular mechanisms governing
osteoclast activation in tumor induced-osteolysis and bone
metastasis formation may result in the development of novel
therapeutic approaches. As several of the osteoclast signal
transduction pathways are also activated in cancer cells,
they might be tackled synergistically within the solid tumor
microenvironment resulting in a parallel reduction in cancer
growth and osteoclast-mediated bone loss. On the other hand,
a precision medicine-based approach is required to overcome
cancer cell resistance mechanisms and to minimize side
effects and interference with the mechanisms of physiological
bone homeostasis. Taken together, pharmacological targeting of
osteoclast and tumor cell signaling pathways may provide novel
approaches to improve the long-term survival of cancer patients
with bone metastases.
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